Searchable abstracts of presentations at key conferences in endocrinology

ea0086p91 | Neuroendocrinology and Pituitary | SFEBES2022

Diabetes insipidus safety: Automated electronic records alert to identify patients with diabetes insipidus in hospital

Clave Llavall Anna , Aquino Maia , Teo James , Mustafa Omar G. , Whitelaw Benjamin C.

Background: Cranial diabetes insipidus (DI) is characterised by the inability to produce vasopressin leading to uncontrolled diuresis. Management includes administering synthetic vasopressin analogue desmopressin (DDAVP). Recently, there have been several national reports of DDAVP omission causing serious patient harm. This study aims to evaluate the feasibility of an automated alert system using Natural Language Processing (NLP) in electronic health records (EHR) to detect DI...

ea0044p79 | Clinical biochemistry | SFEBES2016

Immunoassay cortisol day curve dangerously overestimates cortisol reserve in a metyrapone treated patient

Leong Christine H M , Taylor David R , Gilbert Jackie , Whitelaw Benjamin C

Background: Metyrapone is commonly used in medical management of Cushing’s syndrome. It inhibits 11-β hydroxylase, which catalyses the conversion of 11-deoxycortisol to cortisol. The adequacy of metyrapone blockade can be assessed either clinically or biochemically using a target mean serum cortisol 150–300 nmol/l. Cortisol is normally measured by immunoassay.Case report: A 21-year-old female presented with clinical and biochemical feature...

ea0044p80 | Clinical biochemistry | SFEBES2016

Cortisol measurement using immunoassay versus liquid chromatography-tandem mass spectrometry: metyrapone dose-related discrepancies in cortisol values

Leong Christine H M , Taylor David R , Whitelaw Benjamin C , Aylwin Simon

Background: Metyrapone inhibits 11-β hydroxylase and causes a subsequent rise in the cortisol precursor, 11-deoxycortisol. Cortisol measurements by immunoassays are susceptible to interference and reagent antibody cross-reactivity with cortisol precursors when used in patients receiving metyrapone treatment. Clinicians rely on clinical and biochemical features of cortisol excess for dose titration of this medical blockade. The extent of this interference remains unclear. ...

ea0034p181 | Neoplasia, cancer and late effects | SFEBES2014

Inherited mutations in the SDH complex increase metastatic malignant potential of paragnglioma and phaeochromocytoma tumours

Jafar-Mohammadi Bahram , Izatt Louise , Schulte Klaus-Martin , Carroll Paul V , McGowan Barbara M , Powrie Jake K , Whitelaw Benjamin C , Sarker Debashis , Diaz-Cano Salvador , Aylwin Simon J B

Phaeochromocytomas (PCC) and paraganglioma (PGL) are neural crest tumours arising from the chromaffin producing cells of the adrenal medulla or sympathetic/parasympathetic system respectively. Recently, in part due to advances in high throughput sequencing, our understanding of the genetic predisposition to these tumours has greatly increased. To date, 13 genes have been implicated in the pathogenesis of these conditions (ten available for testing at our centre). Recent studie...

ea0056p41 | Adrenal cortex (to include Cushing's) | ECE2018

Outcomes of patients undergoing surgery for primary aldosteronism based on adrenal venous sampling and/or radiological lateralisation indicate a role for both modalities in case selection

Davis Lauramay , Lewis Dylan , Clough Jennifer , Whitelaw Benjamin C , Gilbert Jackie , Diaz-Cano Salvador , Taylor David R , Vincent Royce P , Hubbard Jonathan , Galata Gabriele , Schulte Klaus-Martin , Aylwin Simon J B

Background: Adrenal venous sampling (AVS) is considered the gold standard for lateralisation of aldosterone production in patients with primary aldosteronism (PA). However, in some patients AVS is not technically successful and management may depend on radiological findings.Aim: To determine 1) the success rate of AVS and 2) the outcomes after surgery related to the lateralisation modality.Method: 156 patients were included who pre...

ea0094op7.1 | RET and Endocrine Cancer | SFEBES2023

Investigating the functional kinome in Multiple Endocrine Neoplasia Type 2

Rix Beatrice , Chauhan Rakhee , Brain Caroline , Kurzawinski Tom R. , Ogunbiyi Olumide K. , Swarbrick Katherine , Nonaka Daisuke , Carroll Paul V. , McGowan Barbara M. , Whitelaw Benjamin C. , McDonald Neil Q. , Grey William , Izatt Louise

Introduction: The age of onset and severity of thyroid disease in MEN2 kindreds can be variable, resulting in wide intrafamilial heterogeneity, despite the same oncogenic driver RET pathogenic variant being present. Our study sought to investigate the RET kinomic landscape in MEN2 to discover new biomarkers and to provide further mechanistic insights into malignant disease progression, focussing on paediatric cases.Metho...

ea0056p140 | Endocrine tumours and neoplasia | ECE2018

Achievement of therapeutic mitotane concentrations in management of advanced adrenocortical cancer: a single centre experience in 47 patients

Bakhit Mohamed , Whitelaw Benjamin C , Gilbert Jackie , Coskeran Patsy , Diaz-Cano Salvador , Taylor David R , Taylor Norman T , Ghatore Lea , Lewis Dylan , Vivian Gillian , Sarker Debashis , Ross Paul , Davis Laura May , Clough Jennifer , Hubbard Johnathan G , Galata Gabriele , Prachalias Andreas , Schulte Klaus-Martin , Aylwin Simon J B

Introduction: Multi-modal therapy for adrenocortical carcinoma (ACC) includes surgery, therapy with the adrenolytic agent mitotane and systemic chemotherapy. Achievement of therapeutic mitotane concentrations (≥14 mg/l) has been related to improved outcomes.Aim: To evaluate the effectiveness of a defined* high dose protocol mitotane therapy in patients with advanced ACC (stages III and IV).Methods: Review of patients presenti...